CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company's surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NYSE
- Symbol: CRY
- CUSIP: 22890310
- Previous Close: $17.25
- 50 Day Moving Average: $18.91
- 200 Day Moving Average: $17.62
- 52-Week Range: $32,848,000.00 - $9.10
- Trailing P/E Ratio: 53.91
- Foreward P/E Ratio: 33.17
- P/E Growth: 1.37
- Market Cap: $555.83M
- Outstanding Shares: 32,848,000
- Beta: 1.23
- Net Margins: 6.00%
- Return on Equity: 8.37%
- Return on Assets: 5.77%
Companies Related to Cryolife:
- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 5.74%
- Quick Ratio: 4.71%
What is Cryolife's stock symbol?
Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."
Where is Cryolife's stock going? Where will Cryolife's stock price be in 2017?
5 analysts have issued 12 month target prices for Cryolife's shares. Their predictions range from $15.00 to $23.50. On average, they expect Cryolife's share price to reach $19.60 in the next year.
When will Cryolife announce their earnings?
Cryolife is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
Who owns Cryolife stock?
Cryolife's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (5.32%), State Street Corp (2.12%), Renaissance Technologies LLC (1.60%), Castleark Management LLC (1.59%), FMR LLC (1.46%) and Royce & Associates LP (0.91%). Company insiders that own Cryolife stock include C Elkins Ronald, David Ashley Lee, James Benson, James P Mackin, Ronald D Mccall, Scott B Capps and Steven G Anderson.
Who sold Cryolife stock? Who is selling Cryolife stock?
Cryolife's stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc., Two Sigma Investments LP, Renaissance Technologies LLC, Royce & Associates LP, Menta Capital LLC, Castleark Management LLC and State Board of Administration of Florida Retirement System. Company insiders that have sold Cryolife stock in the last year include C Elkins Ronald, James Benson, Ronald D Mccall and Scott B Capps.
Who bought Cryolife stock? Who is buying Cryolife stock?
Cryolife's stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Axiom International Investors LLC DE, State Street Corp, Allianz Asset Management AG, FMR LLC, Guggenheim Capital LLC, Russell Investments Group Ltd. and Friess Associates LLC.
How do I buy Cryolife stock?
Shares of Cryolife can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cryolife stock cost?
One share of Cryolife stock can currently be purchased for approximately $17.25.